Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00977925
Registration number
NCT00977925
Ethics application status
Date submitted
15/09/2009
Date registered
16/09/2009
Date last updated
1/10/2015
Titles & IDs
Public title
The Severe Soft Tissue Bleeding Study
Query!
Scientific title
A Phase III Randomized, Controlled, Superiority Study Evaluating the Fibrin Pad Versus Standard of Care Treatment in Controlling Severe Soft Tissue Bleeding During Abdominal, Retroperitoneal, Pelvic, and Thoracic Surgery
Query!
Secondary ID [1]
0
0
400-08-002
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Soft Tissue Bleeding
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - Fibrin Pad
Treatment: Surgery - Standard of Care
Experimental: Fibrin Pad -
Active Comparator: Standard of Care -
Other interventions: Fibrin Pad
Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
Treatment: Surgery: Standard of Care
Standard of Care is a composite of techniques/methods typically used by the surgeon to control severe bleeding.
Query!
Intervention code [1]
0
0
Other interventions
Query!
Intervention code [2]
0
0
Treatment: Surgery
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Proportion of subjects achieving hemostasis at the Target Bleeding Site. Hemostasis is defined as no detectable bleeding at the TBS.
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Intra-operative
Query!
Secondary outcome [1]
0
0
Proportion of subjects achieving hemostatic success at 10 minutes following randomization
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Intra-operative
Query!
Secondary outcome [2]
0
0
Absolute time to hemostasis
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Intra-operative
Query!
Secondary outcome [3]
0
0
Proportion of subjects requiring re-treatment at the TBS prior to wound closure
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Intra-operative
Query!
Secondary outcome [4]
0
0
Incidence of treatment failures
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Intra-operative
Query!
Secondary outcome [5]
0
0
Incidence of adverse events that are potentially related to bleeding at the TBS
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Intra-operative through 60 days
Query!
Secondary outcome [6]
0
0
Incidence of adverse events that are potentially related to thrombotic events;
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Intra-operative through 60 days
Query!
Secondary outcome [7]
0
0
Incidence of adverse events
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Intra-operative through 60 days
Query!
Eligibility
Key inclusion criteria
- Subjects >= 18 years of age, requiring elective, open, abdominal, retroperitoneal,
pelvic or thoracic (non-cardiac) surgical procedures;
- Presence of an appropriate severe bleeding soft tissue Target Bleeding Site (TBS) as
identified intra-operatively by the surgeon;
- Subjects must be willing to participate in the study, and provide written informed
consent.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Subjects with any intra-operative findings identified by the surgeon that may preclude
conduct of the study procedure;
- Bleeding site is from large defects in arteries or veins where the injured vascular
wall requires repair with maintenance of vessel patency and which would result in
persistent exposure of the FP to blood flow and pressure during healing and absorption
of the product;
- Subject with TBS within an actively infected field;
- Bleeding site is in, around, or in proximity to foramina in bone, or areas of bony
confine;
- Subjects with known intolerance to blood products or to one of the components of the
study product;
- Subjects unwilling to receive blood products;
- Subjects with known immunodeficiency diseases (including known HIV);
- Subjects who are known, current alcohol and / or drug abusers;
- Subjects who have participated in another investigational drug or device research
study within 30 days of enrollment;
- Female subjects who are pregnant or nursing.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/08/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/03/2011
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
91
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Bankstown Hospital - Bankstown
Query!
Recruitment hospital [2]
0
0
Flinders Medical Centre - Bedford Park
Query!
Recruitment hospital [3]
0
0
The Townsville Hospital - Douglas
Query!
Recruitment hospital [4]
0
0
Royal Melbourne Hospital - Parkville
Query!
Recruitment postcode(s) [1]
0
0
- Bankstown
Query!
Recruitment postcode(s) [2]
0
0
- Bedford Park
Query!
Recruitment postcode(s) [3]
0
0
- Douglas
Query!
Recruitment postcode(s) [4]
0
0
- Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
Germany
Query!
State/province [1]
0
0
Heidelberg
Query!
Country [2]
0
0
Germany
Query!
State/province [2]
0
0
Homburg/Saar
Query!
Country [3]
0
0
Germany
Query!
State/province [3]
0
0
Karlsruhe
Query!
Country [4]
0
0
New Zealand
Query!
State/province [4]
0
0
Auckland
Query!
Country [5]
0
0
United Kingdom
Query!
State/province [5]
0
0
Birmingham
Query!
Country [6]
0
0
United Kingdom
Query!
State/province [6]
0
0
Cambridge
Query!
Country [7]
0
0
United Kingdom
Query!
State/province [7]
0
0
Edinburgh
Query!
Country [8]
0
0
United Kingdom
Query!
State/province [8]
0
0
Leeds
Query!
Country [9]
0
0
United Kingdom
Query!
State/province [9]
0
0
London
Query!
Country [10]
0
0
United Kingdom
Query!
State/province [10]
0
0
Nottingham
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Ethicon, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The objective of this study is to evaluate the safety and hemostatic effectiveness of the
Fibrin Pad (FP) versus standard of care treatment (SoC) in controlling challenging severe
soft tissue bleeding during abdominal, pelvic, retroperitoneal, and (non-cardiac) thoracic
surgery.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00977925
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
James Hart, MD
Query!
Address
0
0
Ethicon, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00977925
Download to PDF